Amarantus BioScience Inc. - Onwards and Upwards: Building Value from a Solid Foundation


Amarantus BioScience, Inc. (AMBS) (AMBS), a biotechnology company discovering and developing treatmentsand diagnostics for diseases associated with protein misfolding andapoptosis centered around its patented therapeutic proteinMesencephalic Astrocyte-derived Neurotrophic Factor (MANF), todaypublished a blog post on is an exclusive online media publication thatenables key executive officers a unique platform to share insightsabout their company and industry trends.

Amarantus’ President & CEO,Gerald Commissiong, highlighted “several important milestones”the Company has achieved to set the stage for growth in 2013. Mr.Commissiong also addressed what he sees as an “increase in scrutinyas it relates to the manner in which [Amarantus’] data sets arepresented and [the Company’s] financing plans,” providing anupdate to current and potential shareholders alike.

Read the full blog post from GeraldCommissiong on


About AmarantusBioScience, Inc.

AmarantusBioScience, Inc. is adevelopment-stage biotechnology company founded in January 2008. TheCompany has a focus on developing certain biologics surrounding theintellectual property and proprietary technologies it owns to treatand/or diagnose Parkinson’s disease, Traumatic Brain Injury andother human diseases. The Company owns the intellectual propertyrights to a therapeutic protein known asMesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) andis developing MANF-based products as treatments for brain disorders.The Company also is a Founding Member of the Coalition for ConcussionTreatment (#C4CT), a movement initiated in collaboration with BrewerSports International seeking to raise awareness of new treatments indevelopment for concussions and nervous-system disorders. For furtherinformation, please visit


TheChairmansBlog.comis an exclusive, online media publication where publically andprivately held firms alike share insights about their companies andindustries. enables upper tier management todiscuss issues that are of importance to their stakeholders,shareholders, and interested parties in an informal environment. Inaddition to management’s insightful blog posts, staff and aggregate partners contribute articleson finance, technology, health and energy while providing updatedmarket trends news and information.

Forward Looking Statement

This press release containsforward-looking statements within the meaning of the PrivateSecurities Litigation Reform Act of 1995. Such statements include,but are not limited to, statements about the possible benefits ofMANF therapeutic applications and/or advantages presented byAmarantus’ PhenoGuard technology, as well as statements aboutexpectations, plans and prospects of the development of Amarantus’new product candidates. These forward looking statements are subjectto a number of risks, uncertainties and assumptions, including therisks that the anticipated benefits of the therapeutic drugcandidates or discovery platforms, as well as the risks,uncertainties and assumptions relating to the development ofAmarantus’ new product candidates, including those identified under“Risk Factors” in Amarantus’ most recently filed Annual Reporton Form 10-K and Quarterly Report on Form 10-Q and in other filingsAmarantus periodically makes with the SEC. Actual results may differmaterially from those contemplated by these forward-lookingstatements Amarantus does not undertake to update any of theseforward-looking statements to reflect a change in its views or eventsor circumstances that occur after the date of this presentation. Thispress release does not represent an offer to buy or sell securities.

View Comments (0)